Stock TKD TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Takeda Pharmaceutical Company Limited Börse Stuttgart

Equities

TKD

JP3463000004

Real-time Estimate Tradegate
Other stock markets
 05:17:01 2024-07-08 am EDT 		5-day change 1st Jan Change
24.36 EUR +0.56% Intraday chart for Takeda Pharmaceutical Company Limited +0.67% -6.20%
Jul. 03 Blackstone selling Japan drugmaker Alinamin to MBK Partners RE
Jul. 02 Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
China's Supreme People's Court Clarifies Priority Examination Standard in Recent Ruling
AQ
China's SPC Clarifies Priority Examination Standard In Recent Ruling
AQ
Takeda Pharmaceutical : Annual Securities Report (Part 1. Information on Takeda, IV. Information on the Company, 4. Corporate Governance)
PU
Takeda Announces the Publication of its Annual Report on Form 20-F for FY2023
AQ
TAKEDA PHARMACEUTICAL : Form 6 K
PU
Takeda Pharmaceutical : Announces New Assignments of Directors Form 6 K
PU
Takeda Announces New Assignments of Directors
BU
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
BU
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
BU
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
BU
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
AQ
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting
AQ
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat
AQ
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
BU
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K
PU
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
BU
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
BU
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K
PU
TAKEDA PHARMACEUTICAL : Form 6 K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. TKD Stock
  5. News Takeda Pharmaceutical Company Limited
  6. Press Releases